The success of CDNF — fully, cerebral dopamine neurotrophic factor — in improving motor coordination in a mouse model of…
Articles by Steve Bryson, PhD
Higher levels of healthy and mutant huntingtin protein in saliva, but not in blood, are significantly associated with worse motor…
The European Medicines Agency (EMA) has granted orphan drug status to SAGE-718 as a potential therapy for Huntington’s disease. The…
Neuron-targeted treatment based on zinc-finger DNA-binding proteins — called ZFPs — was found to lower brain levels of mutant huntingtin…
The activity of focal adhesion kinase (FAK), an enzyme known to play an essential role in nerve cell function, is…
Beyond genetic factors, the onset of Huntington’s disease later in life was related to being in a stable partnership,…
A 56-year-old man with undiagnosed late-onset Huntington’s disease presented with Parkinson’s disease-like symptoms, including bradykinesia, or slowness of movement,…
Activating the JAK2-STAT3 pathway in astrocyte cells reduced multiple hallmark features of Huntington’s disease — including the toxic clumping…
Clumps of protein resulting from HTT mutations, the underlying cause of Huntington’s disease, form distinct structures in different parts…
The perception of time is impaired in people with symptomatic Huntington’s disease in its early stages — but not…